Pharmaceutical composition comprising mannooligosaccharides derived from coffee for treatment of lifestyle-related disease, and food useful for treatment of lifestyle-related disease
A pharmaceutical composition for preventing or treating lifestyle-related disease is provided. Also provided is a food useful for the prevention or treatment of lifestyle-related disease. The pharmaceutical composition contains, as an active ingredient, a sugar in which a mannose unit makes up 66% or more in terms of the number of mannose units and which has a polymerization degree of 3 to 10.
1. A method for treating lifestyle-related diseases, wherein an effective dose of a pharmaceutical composition is administered to a patient who is at risk of contracting or is suffering from a lifestyle-related disease in an amount effective to reduce liver lipids and/or reduce absorption of sugar in the patient when compared to an individual that is not administered the pharmaceutical composition, the pharmaceutical composition including an effective amount of an active ingredient comprising a sugar with a degree of polymerization of 5-10 and mannose units constituting at least 66% of the numerical content, wherein less than about 1% of the sugar has a degree of polymerization of less than 3, wherein the lifestyle-related disease is selected from the group consisting of obesity, metabolic syndrome, hyperlipidemia, diabetes, hypercholesterolemia, and liver failure, wherein the sugar is obtained by performing hydrolysis treatment on mannan and the mannan is obtained from coffee beans and/or a coffee extract residue.
2. The method according to claim 1 , wherein mannose units constitute at least 90% of the numerical content.
3. The method according to claim 1 , wherein said sugar has a degree of polymerization of 5-10 and consists entirely of mannose units.
4. The method according to claim 3 , wherein said sugar is a β-1,4-mannooligosaccharide.
5. The method according to claim 1 , wherein the active ingredient is provided in an amount effective to reduce lipid absorption.
6. The method according to claim 5 , wherein said lifestyle-related disease is caused by increases in liver lipids.
7. The method according to claim 1 , wherein the active ingredient is provided in an amount effective to reduce sugar absorption.
8. The method according to claim 7 , wherein the active ingredient is provided in an amount effective to reduce liver lipids.
9. The method according to claim 1 , wherein the sugar with a degree of polymerization of 5-10 is obtained by processing mannan contained in raw coffee beans, roasted coffee beans, or used coffee residues with one or more methods selected from the group consisting of acid hydrolysis, high-temperature thermal hydrolysis, oxygen hydrolysis, and microbial fermentation, followed by purification with a process selected from the group consisting of activated carbon treatment, absorbent resin treatment, ion-exchange resin treatment, and ion-exchange membrane treatment.
10. A method for treating lifestyle-related diseases, wherein an effective dose of a pharmaceutical composition is administered to a patient who is at risk of contracting or is suffering from a lifestyle-related disease in an amount effective to reduce liver lipids and/or reduce absorption of sugar in the patient when compared to an individual that is not administered the pharmaceutical composition, the pharmaceutical composition including an effective amount of an active ingredient comprising a sugar with a degree of polymerization of 5-10 and mannose units constituting at least 90% of the numerical content, wherein less than about 1% of the sugar has a degree of polymerization of less than 3, wherein the lifestyle-related disease is selected from the group consisting of obesity, metabolic syndrome, hyperlipidemia, diabetes, hypercholesterolemia, and liver failure, wherein the sugar is obtained by Performing hydrolysis treatment on mannan and the mannan is obtained from coffee beans and/or a coffee extract residue.
11. A method for reducing liver lipids and/or reducing absorption of sugar in a patient, wherein an effective dose of a pharmaceutical composition is administered to the patient in an amount effective to reduce liver lipids and/or reduce absorption of sugar in the patient when compared to an individual that is not administered the pharmaceutical composition, the pharmaceutical composition including an effective amount of an active ingredient comprising a sugar with a degree of polymerization of 5-10 and mannose units constituting at least 66% of the numerical content, wherein less than about 1% of the sugar has a degree of polymerization of less than 3, wherein the sugar is obtained by performing hydrolysis treatment on mannan and the mannan is obtained from coffee beans and/or a coffee extract residue.
12. The method according to claim 11 , wherein mannose units constitute at least 90% of the numerical content.
13. The method according to claim 11 , wherein said sugar has a degree of polymerization of 5-10 and consists entirely of mannose units.
14. The method according to claim 13 , wherein said sugar is a β-1,4-mannooligosaccharide.
15. The method according to claim 11 , wherein the active ingredient is provided in an amount effective to reduce lipid absorption.
16. The method according to claim 11 , wherein the active ingredient is provided in an amount effective to reduce sugar absorption.
17. The method according to claim 16 , wherein the active ingredient is provided in an amount effective to reduce liver lipids.